Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annu... (utics. Sunesis is advancing its productc...)

HOME >> MEDICINE >> TECHNOLOGY

Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting

Date:5/31/2008

utics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

Other trademarks are the property of their respective owners.

Safe Harbor Statement

This press release contains forward-looking statements including without limitation statements related to the potential safety and efficacy and commercial potential of voreloxin (formerly SNS-595), planned additional clinical testing and development efforts, the timing of enrollment in the ongoing Phase 2 clinical trial and the announcement of clinical results. Words such as "promising," "encouraging," "supports," "optimistic," "look forward," "expects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Sunesis' drug discovery and development activities, including enrollment and reporting of results, could be halted significantly or delayed for various reasons, the risk that Sunesis' clinical trials for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval, the risk that preliminary data and trends may not be predictive of future data or results, the risk that Sunesis' preclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies, risks related to the conduct of Sunesis' clinical trials and manufa
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:6/18/2013)... MT. PROSPECT, Ill. , June 18, 2013 ... availability of its new X3130 Appliance Inlet Module. ... thermal circuit breaker , combines a C14 appliance ... in one compact package. This three-in-one device allows ... in their designs - cutting installation time by ...

(Date:6/18/2013)... GARDEN CITY, N.Y. , June 18, 2013 ... announced that it has entered into an exclusive ... and Mid-Atlantic regions with eWellness Corporation ("EWC") for ... "An easy to use physical therapy program ... of diabetes and cardiovascular disease," said Chris ...

(Date:6/18/2013)... a letter to authorities at her hospital, orthopaedic surgeon ... Iowa , writes that a policy of forcing all ... justified nor ethically sound. Her letter is the ... the Journal of American Physicians and Surgeons. ... of 36,000 patients per year die in U.S. hospitals from ...

Breaking Medicine Technology:Three-in-One X3130 Appliance Inlet Module 2 Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 2 Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 3 Mandated Flu Vaccine for Hospital Workers Ethically Questionable, Surgeon Writes 2

[0] Three-in-One X3130 Appliance Inlet Module [0] Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions [0] Mandated Flu Vaccine for Hospital Workers Ethically Questionable, Surgeon Writes

... Ga., Dec. 23, 2010 MiMedx Group, ... integrated developer, manufacturer and marketer of patent protected biomaterial-based ... the Class III certification for a European product using ... certification for "post surgical adhesion inhibiting barriers" is in ...

... Pa., Dec. 23, 2010 Cephalon, Inc. (Nasdaq: ... appointed J. Kevin Buchi as Chief Executive Officer and a ... role of company Chairman in the future. William P. Egan ... "Kevin is an experienced pharmaceutical executive who has been ...

Cached Medicine Technology:MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 2 MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 3 MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 4 Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors 2 Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors 3 Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors 4

MiMedx Receives Additional CE Certification for Its HydroFix™ Technology Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors

(Date:6/19/2013)... Pharmaceutical history is replete with ... with little or no understanding why they work, ... involved emerging years later. When Edward Tobinick ... rapid recovery of cognitive functions after perispinally administering ... known about the role inflammatory processes play in ...

(Date:6/19/2013)... CA (PRWEB) June 19, 2013 Middle ... throughout 2013 across all industries as cash rich buyers ... the differences across industries, all M&A transactions have a ... due diligence to verify the history and quality of ... considered. , But when due diligence involves a ...

(Date:6/19/2013)... Over the past five years, revenue ... has been growing at an annualized rate of 9.5% ... have supported the development of the industry including: substantial ... relatively higher drug prices in hospitals; and people's increased ... the development of chain drug retailing enterprises has also ...

(Date:6/18/2013)... Angeles, CA (PRWEB) June 19, 2013 ... of bariatric surgery, are holding complimentary weight loss seminars ... the detailed program can be accessed at their official ... minimizes surgery and recovery time. Their highly skilled panel ... to bariatric surgery. , A senior executive working ...

(Date:6/18/2013)... 18, 2013 Exposed Skin Care has finally ... acne suffers of all ages finally achieve the clear, beautiful ... products, this new acne clearing system combines the power of ... new acne from forming. , After a quick ... products are some of the most effective available on the ...

Breaking Medicine News(10 mins):Health News:Perispinally Administered Enbrel Facilitates Rapid Recovery of Cognitive Function in Patients with Alzheimer's 2 Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 2 Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 3 Health News:Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld 2 Health News:Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld 3 Health News:oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June 2 Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2 Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3

[0] Perispinally Administered Enbrel Facilitates Rapid Recovery of Cognitive Function in Patients with Alzheimer's [0] Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company [0] Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld [0] oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June [0] Exposed Skin Care Review Released by ExposedSkinCareReview.org

... AUSTIN, Texas Employees who have more control over their ... to be in better health, according to a new study ... month,s Journal of Health and Social Behavior. , "The most ... said lead author John Mirowsky, a sociology professor with the ...

... 18, 2007 -- Phylonix Pharmaceuticals today announced that it ... 135 531 B1: Methods for Introducing Heterologous Cells into ... European countries, encompasses 68 claims, including transplanting stem cells, ... chondrocytes, renal and hepatic cells can be transplanted in ...

... CBS News will be running the,story December 17th and ... CHEMOTHERAPY, THANKS TO A NEW ROBOT THAT MEASURES AND ... PharmD, PhD, and,a patient were interviewed by CBS News. ... compounding for syringes and IV bags.,University of Colorado Hospital ...

... AIDS Healthcare,Foundation (AHF) today strongly criticized Ryan White ... package drafted by Congress in order,to meet the ... for,next year. The fiscal year 2008 Labor-Health and ... today and is,expected to be introduced in the ...

... Toronto Stock Exchange Symbol: CYT, MONTREAL, Dec. 17 ... products to treat cardiovascular,disease, today announced financial results for ... Selected FY 2007 Financial and Operating Highlights:, ... portfolio to ATS Medical, we ...

... ... -, TOPEKA, Kan., Dec. ... Kansas, which will,help support the needs of more than 7,700 Kansas Guard members ... at,TriWest, will present the check to the Adjutant General of the Kansas,National Guard, ...

Creative work has health advantages, Population Research Center study shows Phylonix granted broad European patent for transplanting human cells into zebrafish CytoCare Showcased on CBS News Nationally and CBS Affiliates Ryan White Funding Proposal Demonstrates Neglect of US' Growing AIDS Epidemic, Says AHF CryoCath announces 2007 fourth quarter and fiscal year end financial results TriWest Contributes $15,000 to Kansas National Guard Fund

Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....

Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....

Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....

... 4F, 5F, and 6F ... is ideal for coronary ... state-of-the-art technology and proprietary ... better responsiveness, optimal torque, ...

Medicine Products:

7F High Flow 6F Infiniti 5F Infiniti Infinity